These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 9853077)

  • 1. [Does the growth hormone pharmacokinetic profile help to predict the treatment response?].
    Bozzola M; Radetti G; Elmlinger M; Strasburger CJ
    Arch Pediatr; 1998; 5 Suppl 4():322S-326S. PubMed ID: 9853077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The level of bioavailable growth hormone (GH) after the first GH injection predicts the first year's growth response in GH-deficient children.
    Bozzola M; Radetti G; Pagani S; Draghi M; Aimaretti G; Rondini G
    J Endocrinol Invest; 1999 Nov; 22(10):790-5. PubMed ID: 10614529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic effects of growth hormone administered subcutaneously once or twice daily to growth hormone deficient adults.
    Laursen T; Jørgensen JO; Christiansen JS
    Clin Endocrinol (Oxf); 1994 Sep; 41(3):337-43. PubMed ID: 7525120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant growth hormone (GH) therapy in GH-deficient adults: a long-term controlled study on daily versus thrice weekly injections.
    Amato G; Mazziotti G; Di Somma C; Lalli E; De Felice G; Conte M; Rotondi M; Pietrosante M; Lombardi G; Bellastella A; Carella C; Colao A
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3720-5. PubMed ID: 11061530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations in the oxidant-antioxidant status in prepubertal children with growth hormone deficiency: effect of growth hormone replacement therapy.
    Mohn A; Marzio D; Giannini C; Capanna R; Marcovecchio M; Chiarelli F
    Clin Endocrinol (Oxf); 2005 Nov; 63(5):537-42. PubMed ID: 16268806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioavailability and bioactivity of intravenous vs subcutaneous infusion of growth hormone in GH-deficient patients.
    Laursen T; Møller J; Jørgensen JO; Orskov H; Christiansen JS
    Clin Endocrinol (Oxf); 1996 Sep; 45(3):333-9. PubMed ID: 8949572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of growth hormone administration in pediatric renal allograft recipients.
    Bartosh S; Kaiser B; Rezvani I; Polinsky M; Schulman S; Palmer J; Baluarte HJ
    Pediatr Nephrol; 1992 Jan; 6(1):68-73. PubMed ID: 1536744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The absorption profile and availability of a physiological subcutaneously administered dose of recombinant human growth hormone (GH) in adults with GH deficiency.
    Janssen YJ; Frölich M; Roelfsema F
    Br J Clin Pharmacol; 1999 Mar; 47(3):273-8. PubMed ID: 10215751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and metabolic effects of growth hormone injected subcutaneously in growth hormone deficient patients: thigh versus abdomen.
    Laursen T; Jørgensen JO; Christiansen JS
    Clin Endocrinol (Oxf); 1994 Mar; 40(3):373-8. PubMed ID: 7514513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma integrated concentration of growth hormone after recombinant human growth hormone injection. Implications for determining an optimal dose.
    Chalew SA; Phillip M; Kowarski AA
    Am J Dis Child; 1993 Mar; 147(3):274-8. PubMed ID: 8438807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term results of growth hormone therapy in children with short stature, subnormal growth rate and normal growth hormone response to secretagogues. Dutch Growth Hormone Working Group.
    Wit JM; Boersma B; de Muinck Keizer-Schrama SM; Nienhuis HE; Oostdijk W; Otten BJ; Delemarre-Van de Waal HA; Reeser M; Waelkens JJ; Rikken B
    Clin Endocrinol (Oxf); 1995 Apr; 42(4):365-72. PubMed ID: 7750190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with GHRH(1-29)NH2 in children with idiopathic short stature induces a sustained increase in growth velocity.
    Kirk JM; Trainer PJ; Majrowski WH; Murphy J; Savage MO; Besser GM
    Clin Endocrinol (Oxf); 1994 Oct; 41(4):487-93. PubMed ID: 7955460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of long-term treatment with growth hormone on bone and mineral metabolism in children with growth hormone deficiency.
    Saggese G; Baroncelli GI; Bertelloni S; Cinquanta L; Di Nero G
    J Pediatr; 1993 Jan; 122(1):37-45. PubMed ID: 8419613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of radiation-induced growth hormone deficiency with growth hormone-releasing hormone.
    Ogilvy-Stuart AL; Stirling HF; Kelnar CJ; Savage MO; Dunger DB; Buckler JM; Shalet SM
    Clin Endocrinol (Oxf); 1997 May; 46(5):571-8. PubMed ID: 9231053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rate of change (modulation) of serum growth hormone concentrations is a more important factor in determining growth rate than duration of exposure.
    Hindmarsh PC; Matthews DR; Stratton I; Pringle PJ; Brook CG
    Clin Endocrinol (Oxf); 1992 Feb; 36(2):165-70. PubMed ID: 1568348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nocturnal pulsatile growth hormone releasing hormone treatment in growth hormone deficiency.
    Smith PJ; Brook CG; Rivier J; Vale W; Thorner MO
    Clin Endocrinol (Oxf); 1986 Jul; 25(1):35-44. PubMed ID: 3098459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth hormone treatment of short Chinese children with beta-thalassaemia major without GH deficiency.
    Low LC; Kwan EY; Lim YJ; Lee AC; Tam CF; Lam KS
    Clin Endocrinol (Oxf); 1995 Apr; 42(4):359-63. PubMed ID: 7750189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous absorption kinetics of two highly concentrated preparations of recombinant human growth hormone.
    Laursen T; Jørgensen JO; Susgaard S; Møller J; Christiansen JS
    Ann Pharmacother; 1993 Apr; 27(4):411-5. PubMed ID: 8477114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do growth hormone (GH) serial sampling, insulin-like growth factor-I (IGF-I) or auxological measurements have an advantage over GH stimulation testing in predicting the linear growth response to GH therapy?
    Rogol AD; Blethen SL; Sy JP; Veldhuis JD
    Clin Endocrinol (Oxf); 2003 Feb; 58(2):229-37. PubMed ID: 12580940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diurnal variation in serum insulin-like growth factor (IGF)-I and IGF binding protein-3 concentrations during daily subcutaneous injections of recombinant human growth hormone in GH-deficient adults.
    Oscarsson J; Johannsson G; Johansson JO; Lundberg PA; Lindstedt G; Bengtsson BA
    Clin Endocrinol (Oxf); 1997 Jan; 46(1):63-8. PubMed ID: 9059559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.